Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide for High-risk AML Post-Allo-HSCT
NCT05682755Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Sichuan University. Started Dec 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05682755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682755.